Legendary investor has explained why physical gold is better than Bitcoin.Legendary investor has explained why physical gold is better than Bitcoin.

Bitcoin will never be gold, says Ray Dalio as price jumps above $71,000

2026/03/06 03:44
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

World famous investor Ray Dalio wants a word with the Bitcoin enthusiasts that have touted the top cryptocurrency as gold 2.0.

“There is only one gold,” said Dalio on the All-In podcast on March 3.

The founder of Bridgewater Associates, an investment firm that manages around $125 billion in assets, explained why gold lives in a category of its own — and why the gap between its purported digital copycat is only set to widen.

“Bitcoin does not have privacy,” Dalio said. “Any transactions can be monitored and then indirectly perhaps controlled. Central banks are not going to want to buy Bitcoin and be able to hold it.”

Dalio’s assessment isn’t new. For years, people have been decrying the lack of privacy on Bitcoin. That’s because the system was designed with transparency and trackability in mind, and not necessarily for individuals to conduct anonymous transactions.

Bitcoin is actually pseudonymous: the blockchain records every transaction, but it doesn’t reveal who’s actually moving money.

Gold, instead, can be held physically and transferred without any digital trace, argued Dalio. A central bank can move gold bars between vaults, conduct transactions government-to-government, and maintain complete privacy — no blockchain records the movement.

That fundamental difference, argued Dalio, explains why gold has surged 80% over the past year — to around $5,000 today from roughly $2,900 per ounce — while Bitcoin has fallen 25% since February 2025.

Bitcoin’s other problems

Beyond privacy, Dalio identified three additional headwinds that have made central banks reticent of buying Bitcoin.

First, there’s the quantum computing risk.

“There have been some questions or thoughts of the development of new technologies like quantum computing,” Dalio said. “Can there be issues regarding that?”

Wall Street banking bigwigs have already expressed concern over the issue.

Second, Bitcoin correlates with equities rather than acting as a hedge. It “tends to have a pretty high correlation with the tech stocks,” Dalio noted.

When markets crash, Bitcoin tends to fall alongside risk assets like the Nasdaq instead of rallying like gold.

Finally, argued Dalio, Bitcoin’s size makes it an easy target for manipulation. “It’s a relatively small market that’s relatively controllable,” he added.

Not all bad

Despite Dalio’s scepticism, Bitcoin has its features — especially for individuals and institutions in today’s world.

For one, Bitcoin is much easier to transfer globally. Bitcoin proponents like Michael Saylor have argued that by paying just a few cents, Bitcoin allows anyone with an internet connection to send value around the world 24/7, without armoured trucks or customs forms.

Then there’s divisibility. Bitcoin allows for someone to send $1 or $1 billion, both with the same ease and for a similar cost.

Lest we forget Bitcoin’s scarcity is verifiable — there will only ever be 21 million coins, Bitcoiners say. Anyone can audit the total supply in real-time, whereas gold reserves rely on trust. Countries and their central banks might lie about holdings, and gold-plated tungsten bars have fooled even the most sophisticated of buyers.

But Dalio’s central bank argument remains Bitcoin’s biggest hurdle. Some central banks do, however, like El Salvador, and Bhutan.

But they are an early wave of adopters, and until more governments start to hold Bitcoin in reserves alongside gold, the “digital gold” narrative faces a structural ceiling.

Pedro Solimano is a markets correspondent based in Buenos Aires. Got a tip? Email him at psolimano@dlnews.com.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09